Our goal in type 2 diabetes is to improve glucose and insulin regulation and therefore positively influence HbA1c. Optimization of the central melanocortin system and regulation of the vagal nerve afferents are the primary target areas to allow better glycemic control and potentially reduce the need for pharmaceuticals. Poor regulation of metabolic homeostasis drives the development of obesity. Neurovalens targets key hypothalamic and brainstem nuclei involved in the neuro-regulation of body composition, with the aim of improving this dysregulation at source.

Neurovalens is a global health-tech company that creates non-invasive neurostimulation technology used to treat a range of metabolic and neurological diseases.

Our core value is based on improving the lives of our patients, and is hinged on the generation of robust clinical data that clearly demonstrates meaningful safety and efficacy outcomes.

Our current focus is to provide drug-free treatments within four key health epidemics:

Anxiety
Type 2 Diabetes
Insomnia
Obesity

Neurovalens - Merging Neuroscience & Technology

Applications for Neurovalens Technology

Neuron Pathway Under Neurovalens Technology

How Our Technology Works